Leukemia Clinical Trial
Official title:
A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy For Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML)
RATIONALE: Drugs used in chemotherapy, such as cytarabine and daunorubicin, work in
different ways to stop cancer cells from dividing so they stop growing and die. Monoclonal
antibodies, such as gemtuzumab ozogamicin, can locate cancer cells and either kill them or
deliver cancer-killing substances to them without harming normal cells. Combining
chemotherapy with gemtuzumab ozogamicin may kill more cancer cells. It is not yet known
whether induction therapy using cytarabine and daunorubicin is more effective with or
without gemtuzumab ozogamicin or whether postconsolidation therapy using gemtuzumab
ozogamicin is more effective than no additional therapy in treating de novo (first
occurrence) acute myeloid leukemia.
PURPOSE: This randomized phase III trial is comparing two different regimens of chemotherapy
and monoclonal antibody therapy to see how well they work in treating patients with
previously untreated de novo acute myeloid leukemia.
OBJECTIVES:
- Compare disease-free survival of patients with previously untreated de novo acute
myeloid leukemia treated with induction therapy comprising cytarabine and daunorubicin
with vs without gemtuzumab ozogamicin followed by consolidation therapy comprising
high-dose cytarabine and post-consolidation therapy comprising gemtuzumab ozogamicin vs
no additional therapy.
- Compare the complete remission rate in patients treated with these regimens.
- Compare the frequency and severity of the toxic effects of these regimens in these
patients.
Other objectives (if funding allows):
- Determine the prognostic significance of CD33 expression on the response rate in
patients receiving gemtuzumab ozogamicin.
- Determine the prognostic significance of FLT3 mutations in these patients before
treatment with these regimens.
- Determine the prognostic significance of minimal residual disease in remission
specimens from these patients treated with these regimens.
- Determine the prognostic significance of the flow cytometric detection of minimal
residual disease in specimens collected from these patients treated with these
regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified during induction
therapy according to age (< 35 years vs ≥ 35 years) and during post-consolidation therapy
according to preinduction cytogenetic risk group.
- Induction therapy: Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive daunorubicin IV on days 1-3, cytarabine IV continuously on
days 1-7, and gemtuzumab ozogamicin IV over 2 hours on day 4. Patients receive
filgrastim (G-CSF) or sargramostim (GM-CSF) IV or subcutaneously once daily
beginning on day 15 and continuing until blood counts recover.
- Arm II: Patients receive daunorubicin, cytarabine, and G-CSF or GM-CSF as in arm
I.
Patients in both arms undergo bone marrow aspiration and biopsy on day 14 (and on day 19, if
applicable) and then proceed to reinduction therapy.
- Reinduction therapy: Patients receive daunorubicin IV on days 1-3 and cytarabine IV
continuously on days 1-7. Patients also receive G-CSF or GM-CSF as in induction
therapy.
Patients who achieve A1 bone marrow, B1 peripheral blood, and C1 extramedullary disease
status proceed to consolidation therapy.
- Consolidation therapy: Patients receive high-dose cytarabine IV over 3 hours twice
daily on days 1, 3, and 5. Treatment repeats every 28 days for 3 courses in the absence
of disease progression or unacceptable toxicity.
Patients who maintain A1 bone marrow, B1 peripheral blood, and C1 extramedullary disease
status after consolidation therapy proceed to post-consolidation therapy.
- Post-consolidation therapy: Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive gemtuzumab ozogamicin IV over 2 hours on day 1. Treatment
repeats every 28 days for 3 courses in the absence of disease progression or
unacceptable toxicity.
- Arm II: Patients receive no additional therapy. Patients are observed at days 30
and 60 after randomization.
Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then
annually for 3 years.
PROJECTED ACCRUAL: A total of 684 patients (342 per treatment arm) will be accrued for this
study within 4.5-5 years.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |